Anticancer agent 56
Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with agent-likeness properties, possessing anticancer activity against several cancer cell lines (IC50<3 μM). Anticancer agent 56 induces cell cycle arrest at G2/M phase and triggers mitochondrial apoptosis pathway. Anticancer agent 56 acts by accumulation of ROS, up regulation of BAX, down regulation of Bcl-2 and activation of caspases 3, 7, 9.
For research use only. We do not sell to patients.
- CAS No.: 2241915-59-1
- Formula: C20H18ClN3O3
- Molecular Weight:383.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
IC50: 0.64 ± 0.02 μM in Leukemia RPMI-8226, 0.96 ± 0.04 μM in Leukemia SR, 0.84 ± 0.07 μM in Leukemia K-562, 0.69 ± 0.01 μM in Melanoma M14, 0.24 ± 0.01 μM in Breast MCF7, 0.26 ± 0.01 μM in Colon HCT116, 2.95 ± 0.14 μM in Prostate PC3[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCD-18Co | IC50 |
17.15 μM
Compound: 4d
|
Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
| HCT-116 | IC50 |
0.26 μM
Compound: 4d
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
| K562 | IC50 |
0.84 μM
Compound: 4d
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
| K562 | IC50 |
0.84 μM
Compound: 14
|
Antiproliferative activity against human K562 cells
Antiproliferative activity against human K562 cells
|
[PMID: 38889607] |
| Leukemia cell | IC50 |
0.96 μM
Compound: 14
|
Cytotoxicity against human Leukemia cancer cells
Cytotoxicity against human Leukemia cancer cells
|
[PMID: 38889607] |
| M14 | IC50 |
0.69 μM
Compound: 4d
|
Cytotoxicity against human M14 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human M14 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
| MCF-10A | IC50 |
25 μM
Compound: 4d
|
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
| MCF7 | IC50 |
0.24 μM
Compound: 4d
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
| PC-3 | IC50 |
2.95 μM
Compound: 4d
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
| RPMI-8226 | IC50 |
0.64 μM
Compound: 4d
|
Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
| RPMI-8226 | IC50 |
0.64 μM
Compound: 14
|
Antiproliferative activity against human RPMI-8226 cells
Antiproliferative activity against human RPMI-8226 cells
|
[PMID: 38889607] |
| SR | IC50 |
0.96 μM
Compound: 4d
|
Cytotoxicity against human SR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human SR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31986406] |
Chemical Information
-
CAS No. 2241915-59-1
-
Molecular Weight 383.83
-
Formula C20H18ClN3O3
-
SMILES
COC1=C(C=C(C=C1)/C=C/C(C2=C(N(N=N2)C3=CC=C(C=C3)Cl)C)=O)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)